Posted January 6, 2009
BioDelivery Sciences signs $6M partnership deal for lead drug candidate
Post a comment
Print this storyE-mail story
Share
Raleigh, N.C. —
BioDelivery Sciences (Nasdaq: BDSI) has signed a deal worth $6 million with its international partner for distribution of its powerful drug that targets breakthrough cancer pain.
BDSI received $3 million from Meda AB for rights to sell the drug, called Onsolis, in all countries except Taiwan and South Korea.
Meda AB also provided BDSI with a $3 million advance out of a forthcoming milestone payment estimated at $30 million.
Meda AB already owned distribution rights to Onsolis in the U.S., Europe, Canada and Mexico.
Onsolis is still being reviewed by the U.S. Food and Drug Administration. The drug includes a powerful opiate.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
